Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A single dose of rademikibart dramatically cut hospital and ER returns for COPD patients in a new phase 2 trial. The add-on biologic reduced treatment failures by 81% and eliminated all ED visits and hospital admissions over four weeks compared to placebo. Connect Biopharma is now planning to engage with the FDA about a phase 3 program.
A single subcutaneous dose of rademikibart, added to standard of care, delivered striking results for COPD patients with type 2 inflammation in the phase 2 Seabreeze STAT COPD trial. Across 159 patients seen at urgent outpatient visits, EDs, or hospitals, the biologic cut treatment failure rates by 81% over four weeks compared to placebo — with zero hospitalizations or ED visits in the rademikibart group versus seven in the placebo group.
Beyond keeping patients out of the hospital, rademikibart also reduced new moderate-to-severe exacerbations by 85%, lowered daily rescue inhaler use across multiple weeks, and improved patient-reported symptom scores. The safety profile also looked favorable, with fewer adverse events in the treatment group.
By the Numbers:
Why it matters: COPD exacerbations are a leading driver of hospitalizations and healthcare costs. A single-dose biologic that meaningfully reduces readmissions and complications could reshape acute COPD management — and Connect Biopharma is already eyeing a phase 3 FDA registration program.
